EGPAF Country Fact Sheet: Eswatini

Background The Botswana Tsepamo study identified an initial neural tube defect (NTD) safety signal with dolutegravir antiretroviral therapy (ART) exposure at conception. We conducted similar surveillance in 5 hospitals in Eswatini from September 2021 to September 2023 to evaluate the prevalence of birth defects and adverse pregnancy outcomes by maternal HIV status and ART regimen/timing. […]

Background: We assessed clinical outcomes among children, adolescents, and people younger than 25 years on darunavir-based antiretroviral therapy (ART) in 9 sub-Saharan African countries. Setting: Third-line ART centers in Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe. Methods: From January 2019 to December 2022, we collected data from a cohort of children, adolescents, and young people […]

Recommendations on breastfeeding by persons living with HIV (PLWH) have shifted globally over time. Because the absolute risk for HIV transmission through breast milk in the absence of antiretroviral therapy (ART) is as high as 16% to 20%, recommendations for low-resource settings in the early 1990s initially emphasized replacement feeding if acceptable, feasible, affordable, sustainable, […]